Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Down 13.8% in March

Bone Biologics Corp. (NASDAQ:BBLG) was the recipient of a significant decline in short interest in March. As of March 13th, there was short interest totaling 26,183 shares, a decline of 13.8% from the February 26th total of 30,363 shares. Currently, 1.6% of the company’s shares are short sold. Based on an average trading volume of 30,831 shares, the short-interest ratio is currently 0.8 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bone Biologics in a report on Friday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Bone Biologics Stock Up 5.5%

Shares of NASDAQ:BBLG traded up $0.06 during midday trading on Wednesday, reaching $1.16. 2,356 shares of the company were exchanged, compared to its average volume of 25,246. The firm has a market cap of $2.09 million, a PE ratio of -0.31 and a beta of 0.78. Bone Biologics has a fifty-two week low of $1.05 and a fifty-two week high of $6.75. The stock has a fifty day simple moving average of $1.31 and a two-hundred day simple moving average of $1.73.

Bone Biologics (NASDAQ:BBLG) last announced its earnings results on Monday, March 2nd. The company reported ($0.34) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.34). As a group, analysts forecast that Bone Biologics will post -5 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC grew its holdings in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,576 shares of the company’s stock after buying an additional 12,549 shares during the quarter. DRW Securities LLC owned approximately 1.31% of Bone Biologics worth $34,000 at the end of the most recent reporting period. 34.30% of the stock is currently owned by institutional investors and hedge funds.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.